Russia approved list of 96 bio-targets to develop the medicinal products analogues

Print 16 June 2017
GMP News

On June 8, 2016, the Russian Ministry of Justice registered the joint Order of the Ministry of Industry and Trade and the Ministry of Health of Russia “On Approval of the List of Bio-Targets for Developing the Analogues of Innovative Medicinal Products With Similar and Improved Pharmacotherapeutic Effect.” The list includes 96 items.

The list of bio-targets serves as a reference for organizations, that are involved in the research of new medicinal products and claim compensation of development costs under the subsidy mechanism provided for by the Decree of the Government of the Russian Federation within the state program “Development of Pharmaceutical and Medical Industry” for 2013-2020.

The new mechanism is the embodiment of the development strategy of Russian pharmaceutical industry, which implies its transition to innovative development model by 2020.

Since June 14, 2016, the Ministry of Industry and Trade of Russia is accepting the applications from organizations to subsidize the development of innovative medicinal products.

Source

Return